Jefferies Financial Group Weighs in on Zealand Pharma A/S’s FY2021 Earnings (NASDAQ:ZEAL)

Zealand Pharma A/S (NASDAQ:ZEAL) – Analysts at Jefferies Financial Group issued their FY2021 earnings estimates for Zealand Pharma A/S in a research report issued on Tuesday, January 11th. Jefferies Financial Group analyst L. Codrington anticipates that the company will post earnings per share of ($3.67) for the year. Jefferies Financial Group currently has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Zealand Pharma A/S’s Q4 2021 earnings at ($1.07) EPS, FY2022 earnings at ($4.89) EPS, FY2023 earnings at ($3.64) EPS, FY2024 earnings at ($2.65) EPS and FY2025 earnings at $0.06 EPS.

Zealand Pharma A/S (NASDAQ:ZEAL) last posted its quarterly earnings data on Wednesday, November 10th. The company reported ($4.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($6.31) by $1.70. The business had revenue of $16.87 million during the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative return on equity of 82.62% and a negative net margin of 371.32%. During the same period last year, the company earned ($0.90) earnings per share.

Separately, Zacks Investment Research raised Zealand Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 17th.

ZEAL opened at $21.38 on Thursday. Zealand Pharma A/S has a 12-month low of $19.33 and a 12-month high of $38.21. The stock has a market cap of $932.90 million, a price-to-earnings ratio of -4.93 and a beta of 1.23. The business has a 50 day moving average of $22.45 and a 200-day moving average of $27.56.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley lifted its stake in shares of Zealand Pharma A/S by 7.6% in the 3rd quarter. Morgan Stanley now owns 6,553 shares of the company’s stock valued at $193,000 after purchasing an additional 463 shares during the period. Jacobi Capital Management LLC bought a new position in Zealand Pharma A/S during the second quarter valued at $27,000. BlackRock Inc. grew its holdings in Zealand Pharma A/S by 37.3% during the third quarter. BlackRock Inc. now owns 4,028 shares of the company’s stock valued at $119,000 after purchasing an additional 1,095 shares during the period. Finally, OLD Mission Capital LLC bought a new position in Zealand Pharma A/S during the second quarter valued at $370,000. 1.78% of the stock is currently owned by hedge funds and other institutional investors.

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Soborg, Denmark.

Further Reading: Candlestick

Earnings History and Estimates for Zealand Pharma A/S (NASDAQ:ZEAL)

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.